Martyn Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Martyn Thomas has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Dominique Himbert
2 shared publicationsGerhard Schymik
2 shared publicationsHendrik Treede
2 shared publicationsHolger Eggebrecht
2 shared publicationsOlaf Wendler
2 shared publicationsPaolo Rubino
2 shared publications
Latest Publications
- Open Access
- 24 July 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-8
The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial
Current guidelines recommend treatment of significant coronary artery disease by concomitant coronary artery bypass grafting (CABG) in patients undergoing surgical aortic valve replacement. However there is no consensus as to how best to treat coronary disease in high-risk patients requiring transcatheter aortic valve implantation (TAVI). The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial is a randomized, controlled open-label trial of 310 patients randomized to treatment of significant coronary artery disease by percutaneous coronary intervention (PCI - test arm) or no PCI (control arm). Significant coronary disease is defined as ≥1 lesion of ≥70% severity in a major epicardial vessel or 50% in a vein graft or protected left main stem lesion. The trial tests the hypothesis that the strategy of performing pre-TAVI PCI is non-inferior to not treating such coronary stenoses with PCI prior to TAVI, with a composite primary outcome of 12-month mortality and rehospitalization. Secondary outcomes include efficacy end-points such as 30-day mortality, safety endpoints including bleeding, burden of symptoms, and quality of life (assessed using the Seattle Angina Questionnaire and the Kansas City Cardiomyopathy Questionnaire). In conclusion, we hope that using a definition of coronary artery disease severity closer to that used in everyday practice by interventional cardiologists - rather than the 50% severity used in surgical guidelines - will provide robust evidence to direct guidelines regarding TAVI therapy and improve its safety and efficacy profile of this developing technique. ISRCTN75836930 , http://www.controlled-trials.com/ ISRCTN75836930 (registered 19 November 2011).
- 24 July 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-8
Open AccessThe percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial
Current guidelines recommend treatment of significant coronary artery disease by concomitant coronary artery bypass grafting (CABG) in patients undergoing surgical aortic valve replacement. However there is no consensus as to how best to treat coronary disease in high-risk patients requiring transcatheter aortic valve implantation (TAVI). The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial is a randomized, controlled open-label trial of 310 patients randomized to treatment of significant coronary artery disease by percutaneous coronary intervention (PCI - test arm) or no PCI (control arm). Significant coronary disease is defined as ≥1 lesion of ≥70% severity in a major epicardial vessel or 50% in a vein graft or protected left main stem lesion. The trial tests the hypothesis that the strategy of performing pre-TAVI PCI is non-inferior to not treating such coronary stenoses with PCI prior to TAVI, with a composite primary outcome of 12-month mortality and rehospitalization. Secondary outcomes include efficacy end-points such as 30-day mortality, safety endpoints including bleeding, burden of symptoms, and quality of life (assessed using the Seattle Angina Questionnaire and the Kansas City Cardiomyopathy Questionnaire). In conclusion, we hope that using a definition of coronary artery disease severity closer to that used in everyday practice by interventional cardiologists - rather than the 50% severity used in surgical guidelines - will provide robust evidence to direct guidelines regarding TAVI therapy and improve its safety and efficacy profile of this developing technique. ISRCTN75836930 , http://www.controlled-trials.com/ ISRCTN75836930 (registered 19 November 2011).
- 1 May 2014
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 56 (6) , 625-634
European Experience and Perspectives on Transcatheter Aortic Valve Replacement
- 1 May 2014
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 56 (6) , 625-634
European Experience and Perspectives on Transcatheter Aortic Valve Replacement
- Top Cited Papers
- 26 July 2011
- Published by Wolters Kluwer Health in Circulation
- Vol. 124 (4) , 425-433
One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry
Background—: Transcatheter aortic valve implantation was developed to provide a therapeutic option for patients considered to be ineligible for, and to mitigate mortality and morbidity associated with, high-risk surgical aortic valve replacement. Methods and Results—: The Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess initial post commercial clinical transcatheter aortic valve implantation results of the Edwards SAPIEN valve in consecutive patients in Europe. Cohort 1 consists of 1038 patients enrolled at 32 centers. One-year outcomes are presented. Patients with the transapical approach (n=575) suffered more comorbidities than transfemoral patients (n=463) with a significantly higher logistic EuroSCORE (29% versus 25.8%; P =0.007). These groups are different; therefore, outcomes cannot be directly compared. Total Kaplan Meier 1-year survival was 76.1% overall, 72.1% for transapical and 81.1% for transfemoral patients, and 73.5% of surviving patients were in New York Heart Association (NYHA) class I or II at 1 year. Combined transapical and transfemoral causes of death were cardiac in 25.1%, noncardiac in 49.2%, and unknown in 25.7%. Pulmonary complications (23.9%), renal failure (12.5%), cancer (11.4%), and stroke (10.2%) were the most frequent noncardiac causes of death. Multivariable analysis identified logistic EuroSCORE, renal disease, liver disease, and smoking as variables with the highest hazard ratios for 1-year mortality whereas carotid artery stenosis, hyperlipidemia, and hypertension were associated with lower mortality. Conclusion—: The SOURCE Registry is the largest consecutively enrolled registry for transcatheter aortic valve implantation procedures. It demonstrates that with new transcatheter aortic techniques excellent 1-year survival in high-risk and inoperable patients is achievable and provides a benchmark against which future transcatheter aortic valve implantation cohorts and devices can be measured.
- 26 July 2011
- Published by Wolters Kluwer Health in Circulation
- Vol. 124 (4) , 425-433
Top Cited PapersOne-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry
Background—: Transcatheter aortic valve implantation was developed to provide a therapeutic option for patients considered to be ineligible for, and to mitigate mortality and morbidity associated with, high-risk surgical aortic valve replacement. Methods and Results—: The Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess initial post commercial clinical transcatheter aortic valve implantation results of the Edwards SAPIEN valve in consecutive patients in Europe. Cohort 1 consists of 1038 patients enrolled at 32 centers. One-year outcomes are presented. Patients with the transapical approach (n=575) suffered more comorbidities than transfemoral patients (n=463) with a significantly higher logistic EuroSCORE (29% versus 25.8%; P =0.007). These groups are different; therefore, outcomes cannot be directly compared. Total Kaplan Meier 1-year survival was 76.1% overall, 72.1% for transapical and 81.1% for transfemoral patients, and 73.5% of surviving patients were in New York Heart Association (NYHA) class I or II at 1 year. Combined transapical and transfemoral causes of death were cardiac in 25.1%, noncardiac in 49.2%, and unknown in 25.7%. Pulmonary complications (23.9%), renal failure (12.5%), cancer (11.4%), and stroke (10.2%) were the most frequent noncardiac causes of death. Multivariable analysis identified logistic EuroSCORE, renal disease, liver disease, and smoking as variables with the highest hazard ratios for 1-year mortality whereas carotid artery stenosis, hyperlipidemia, and hypertension were associated with lower mortality. Conclusion—: The SOURCE Registry is the largest consecutively enrolled registry for transcatheter aortic valve implantation procedures. It demonstrates that with new transcatheter aortic techniques excellent 1-year survival in high-risk and inoperable patients is achievable and provides a benchmark against which future transcatheter aortic valve implantation cohorts and devices can be measured.
- 1 November 2010
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 3 (11) , 1103-1109
The Global Experience With Percutaneous Aortic Valve Replacement
- 1 November 2010
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 3 (11) , 1103-1109
The Global Experience With Percutaneous Aortic Valve Replacement
- Top Cited Papers
- 6 July 2010
- Published by Wolters Kluwer Health in Circulation
- Vol. 122 (1) , 62-69
Thirty-Day Results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry
Background— Transcatheter aortic valve implantation was developed to mitigate the mortality and morbidity associated with high-risk traditional aortic valve replacement. The Edwards SAPIEN valve was approved for transcatheter aortic valve implantation transfemoral delivery in the European Union in November 2007 and for transapical delivery in January 2008. Methods and Results— The SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess the initial clinical results of the Edwards SAPIEN valve in consecutive patients in Europe after commercialization. Cohort 1 consists of 1038 patients enrolled at 32 centers. Patients who were treated with the transapical approach (n=575) suffered more comorbidities than the transfemoral patients (n=463), resulting in a significantly higher logistic EuroSCORE (29.1% versus 25.7%; P Conclusion— Technical proficiency can be learned and adapted readily as demonstrated by the short-term procedural success rate and low 30-day mortality rates reported in the SOURCE Registry. Specific complication management and refinement of patient selection are needed to further improve outcomes.
- 6 July 2010
- Published by Wolters Kluwer Health in Circulation
- Vol. 122 (1) , 62-69
Top Cited PapersThirty-Day Results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry
Background— Transcatheter aortic valve implantation was developed to mitigate the mortality and morbidity associated with high-risk traditional aortic valve replacement. The Edwards SAPIEN valve was approved for transcatheter aortic valve implantation transfemoral delivery in the European Union in November 2007 and for transapical delivery in January 2008. Methods and Results— The SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess the initial clinical results of the Edwards SAPIEN valve in consecutive patients in Europe after commercialization. Cohort 1 consists of 1038 patients enrolled at 32 centers. Patients who were treated with the transapical approach (n=575) suffered more comorbidities than the transfemoral patients (n=463), resulting in a significantly higher logistic EuroSCORE (29.1% versus 25.7%; P Conclusion— Technical proficiency can be learned and adapted readily as demonstrated by the short-term procedural success rate and low 30-day mortality rates reported in the SOURCE Registry. Specific complication management and refinement of patient selection are needed to further improve outcomes.
Trans-catheter aortic valve implantation in the United Kingdom: NICE guidance
Surgical aortic valve replacement (AVR) is undoubtedly the “gold standard” procedure for symptomatic aortic stenosis with excellent short-term and long-term results, even in high-risk patients.2 3 Despite this, surveys have shown that many patients are excluded from this procedure, often because of co-morbidities.4 The prognosis in these patients is poor. The need …
Trans-catheter aortic valve implantation in the United Kingdom: NICE guidance
Surgical aortic valve replacement (AVR) is undoubtedly the “gold standard” procedure for symptomatic aortic stenosis with excellent short-term and long-term results, even in high-risk patients.2 3 Despite this, surveys have shown that many patients are excluded from this procedure, often because of co-morbidities.4 The prognosis in these patients is poor. The need …
PCI or CABG: which patients and at what cost?
Some have interpreted the recently published COURAGE trial,2 which randomised (after coronary angiography) 2287 patients with positive non-invasive tests to either optimal medical treatment (OMT) or PCI, as indicating that OMT is equivalent to PCI for stable coronary artery disease and suggested that PCI is an overcostly, overused procedure. The 4.6-year composite of death/non-fatal myocardial infarction was 19.0% for PCI with OMT and 18.5% for OMT alone (p = 0.62). The relevance of this study to UK practice is doubtful since angioplasty in the UK is generally reserved for patients who have continuing symptoms despite OMT, although clearly there are patients who undergo PCI where there is clear evidence on objective non-invasive testing of silent ischaemia and a significant lesion in the same territory.
PCI or CABG: which patients and at what cost?
Some have interpreted the recently published COURAGE trial,2 which randomised (after coronary angiography) 2287 patients with positive non-invasive tests to either optimal medical treatment (OMT) or PCI, as indicating that OMT is equivalent to PCI for stable coronary artery disease and suggested that PCI is an overcostly, overused procedure. The 4.6-year composite of death/non-fatal myocardial infarction was 19.0% for PCI with OMT and 18.5% for OMT alone (p = 0.62). The relevance of this study to UK practice is doubtful since angioplasty in the UK is generally reserved for patients who have continuing symptoms despite OMT, although clearly there are patients who undergo PCI where there is clear evidence on objective non-invasive testing of silent ischaemia and a significant lesion in the same territory.
- Open Access
Are drug eluting stents really worth the money?
The cost effectiveness of drug eluting stents is being called into question. But is this fair in the light of all the available clinical data?
Open AccessAre drug eluting stents really worth the money?
The cost effectiveness of drug eluting stents is being called into question. But is this fair in the light of all the available clinical data?
- Open Access
Brachytherapy: here today, gone tomorrow?
The efficacy of intracoronary brachytherapy for the treatment of de novo coronary disease and ISR was proven in animals1, 2 and subsequently in a number of human registries,3 single centre4, 5 and multicentre randomised trials6, 7 for both β and γ radiation. Setting up a brachytherapy programme was, however, complex because of the need for cardiologists to gain therapeutic radiation licenses in association with medical oncologists and medical physicists. This process led to a reputation that the procedure itself was “difficult and complex” and certainly limited the uptake of the technique among the interventional community, despite the compelling clinical data.
Open AccessBrachytherapy: here today, gone tomorrow?
The efficacy of intracoronary brachytherapy for the treatment of de novo coronary disease and ISR was proven in animals1, 2 and subsequently in a number of human registries,3 single centre4, 5 and multicentre randomised trials6, 7 for both β and γ radiation. Setting up a brachytherapy programme was, however, complex because of the need for cardiologists to gain therapeutic radiation licenses in association with medical oncologists and medical physicists. This process led to a reputation that the procedure itself was “difficult and complex” and certainly limited the uptake of the technique among the interventional community, despite the compelling clinical data.